Drug Profile

Mercaptopurine oral suspension

Alternative Names: Allmercap; Purixan; Xaluprine

Latest Information Update: 16 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Nova Laboratories
Class Antineoplastics; Purines; Small molecules; Sulfhydryl compounds
Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Precursor cell lymphoblastic leukaemia-lymphoma
New Molecular Entity No

Highest Development Phases

Marketed Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

08 Apr 2015 The product is approved for Acute lymphoblastic leukaemia in European Union
18 Feb 2015 Launched for Acute lymphoblastic leukaemia in USA and Czech Republic (PO) prior to February 2015
17 Jun 2014 Mercaptopurine oral suspension licensed to LINK Healthcare in Australia

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com